Danaher Co. (NYSE:DHR) Shares Acquired by Choreo LLC

Choreo LLC boosted its position in Danaher Co. (NYSE:DHR) by 4.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,703 shares of the conglomerate’s stock after purchasing an additional 911 shares during the period. Choreo LLC’s holdings in Danaher were worth $4,984,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Tectonic Advisors LLC lifted its holdings in shares of Danaher by 7.6% in the fourth quarter. Tectonic Advisors LLC now owns 3,350 shares of the conglomerate’s stock valued at $769,000 after buying an additional 238 shares during the period. Nvwm LLC grew its stake in shares of Danaher by 1.6% in the 4th quarter. Nvwm LLC now owns 5,592 shares of the conglomerate’s stock worth $1,284,000 after purchasing an additional 89 shares during the last quarter. Confluence Wealth Services Inc. raised its holdings in shares of Danaher by 4.3% in the 4th quarter. Confluence Wealth Services Inc. now owns 2,904 shares of the conglomerate’s stock worth $713,000 after purchasing an additional 120 shares in the last quarter. Osprey Private Wealth LLC lifted its stake in Danaher by 1.1% during the fourth quarter. Osprey Private Wealth LLC now owns 11,250 shares of the conglomerate’s stock valued at $2,582,000 after purchasing an additional 125 shares during the last quarter. Finally, Stratos Investment Management LLC boosted its holdings in Danaher by 19.7% during the fourth quarter. Stratos Investment Management LLC now owns 1,618 shares of the conglomerate’s stock worth $371,000 after buying an additional 266 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $211.92 on Thursday. The firm has a market cap of $153.07 billion, a P/E ratio of 40.14, a PEG ratio of 2.80 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a fifty-two week low of $210.04 and a fifty-two week high of $281.70. The stock’s 50-day moving average is $234.50 and its two-hundred day moving average is $252.68.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm earned $2.09 EPS. Analysts predict that Danaher Co. will post 7.77 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.51%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Analysts Set New Price Targets

A number of brokerages have recently commented on DHR. Wells Fargo & Company cut their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.